Mayday Healthcare Plc

Mayday Healthcare has been an established Nursing Agency since December 2003. Our aim is to provide an effective temporary healthcare recruitment service to both our clients and our candidates. We are part of The National Agency Nursing Framework Agreement and have added national contracts with the Spire Group and BMI Hospitals. This shows that we are now well positioned to provide around the clock service to healthcare organisations in both the public and private sectors alike.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

news image

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

news image

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More

LEXOGEN AND ONRAMP BIOINFORMATICS PARTNER TO PROVIDE DIFFERENTIAL GENE EXPRESSION DATA ANALYSIS AND INTERPRETATION FOR QUANTSEQ 3' MRNA-SEQ USERS

Lexogen | June 17, 2020

news image

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

Read More

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

news image

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More
news image

CELL AND GENE THERAPY

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More
news image

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More
news image

LEXOGEN AND ONRAMP BIOINFORMATICS PARTNER TO PROVIDE DIFFERENTIAL GENE EXPRESSION DATA ANALYSIS AND INTERPRETATION FOR QUANTSEQ 3' MRNA-SEQ USERS

Lexogen | June 17, 2020

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

Read More
news image

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us